Call for scientific collaboration to support genomic-based surveillance of Neisseria gonorrhoeae-antimicrobial resistance at EU-level
ECDC is looking to establish a scientific collaboration with an organisation which can perform whole genome sequencing (WGS) of Neisseria gonorrhoeae, carry out related data analyses, share results of the analyses with ECDC and the participants of the European Gonococcal Antimicrobial Surveillance Programme as well as visualise the results.
Second European HIV testing week kicks off today
From 21 to 28 November 2014, nearly 700 organisations across Europe will host activities to increase awareness of the personal and public health benefits of HIV testing. As HIV infection can remain asymptomatic for a long time and a substantial number of infected persons across Europe are unaware of their infection, ECDC supports the aims of this second European HIV testing week.
Gonorrhoea strains across Europe becoming more susceptible to main treatment options
According to test results from the annual European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), resistance levels to the main antimicrobials used for treatment of gonorrhoea infection have seen an encouraging decrease since 2010.
Understanding drug-resistant gonorrhoea: an ECDC whole genome sequencing study
Can whole genome sequencing illustrate changes in drug susceptibility of gonorrhoea to antimicrobials used for treatment and so help to define more effective treatment regimens? The first study of this kind within an international surveillance programme for sexually transmitted infections shows distribution of drug-resistant gonorrhoea strains across Europe.
Drug-resistance of gonorrhoea in the EU: persistent but stable
Neisseria gonorrhoea continues to show high levels of resistance to azithromycin across the European Union and European Economic Area, according to the 2016 results of the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP).
3rd Meeting of the Hepatitis B and C Network
On the third meeting of the Hepatitis B and C Network national focal points and experts discussed the enhanced surveillance programme for hepatitis B and C across Europe and explored ways of improving it.